HomeStocksAARTIPHARM

A

Aarti Pharma Labs

AARTIPHARM Share PriceHealthcare

₹ 858.80

-9.30 (-1.07%)loss
as on 04 Sep 2026 at 03:50 PM
views46
analyst100% Hold
Overview
Pros & Cons
News
History
Fundamentals
Investment Returns
Technicals
Financials
Balance Sheet
Cash Flow
Corporate Actions
Peers

Aarti Pharma Labs Share Price Today

Today Aarti Pharma Labs opened at 872.00 while its previous close was at 868.10. In todays trading session AARTIPHARM reached a high of 879.75 and low of 854.10. The average traded price for today is 862.15. The 50 DMA stands at 751.91 and 200 DMA is at 719.04. Looking at intraday trend, the stock is in Downtrend.

50 DMA: 751.91200 DMA: 719.04
chartsarrowTradingViewarrow

Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.

Use Chart

AARTIPHARM Stock Performance

Markets Today

High

879.75

Low

854.10

Open at

872.00

Prev Close

868.10

Volumes

4,63,265

Avg Price

862.15

Lower Circuit

687.05

Upper Circuit

1,030.55

Last Traded Details

Quantity

57

Time

15:50:04

Price Movement

854.10879.75
0.55%Loss
down side
up side
2.38%Profit

Historical Performance

3 M High

932.60

3 M Low

604.15

1 Yr High

946.10

1 Yr Low

585.00

3 Yr High

971.00

3 Yr Low

371.10

5 Yr High

971.00

5 Yr Low

234.80

1-Year Performance

585.00946.10
46.80%Loss
down side
up side
9.23%Profit
View In-Deptharrow

AARTIPHARM Pros and Cons

byfuzz AI

Consolidated operational revenue grows from ₹3,862 Cr to ₹5,358 Cr from Q1 FY26 to Q1 FY27, driving strong top-line momentum.

Xanthine derivatives revenue share rebounds from 49.6% to 57% from Q1 FY26 to Q1 FY27, highlighting segment resurgence.

Regulated market share expands from 49% to 58% from Q1 FY26 to Q1 FY27, confirming premium market penetration.

Profit after tax surges from ₹495 Cr to ₹761 Cr from Q1 FY26 to Q1 FY27, confirming bottom-line expansion.

Joint venture contribution turns positive, growing from a loss of ₹18 Cr to a gain of ₹74 Cr from Q1 FY26 to Q1 FY27, indicating successful partnership turnaround.

International sales share falls from 56% to 48% from Q1 FY26 to Q1 FY27, indicating export softness.

Operating expenses rise from ₹2,801 Cr to ₹4,032 Cr from Q1 FY26 to Q1 FY27, signaling cost inflation pressure.

API & Intermediates revenue share declines from 40.8% to 30% from Q1 FY26 to Q1 FY27, reflecting portfolio mix dilution.

Average trading volume drops from 496.56 to 267.71 from Q1 FY26 to Q1 FY27, warning of liquidity drain.

Depreciation and amortization increases from ₹228 Cr to ₹300 Cr from Q1 FY26 to Q1 FY27, signaling heavy capex depreciation burden.

fuzz Insights
Positive

Factory profits barely moved, but take-home pay jumped.

Positive

Heavy equipment write-downs failed to crush profit rates.

Positive

Debt payments stayed heavy, but profit rates still climbed.

Positive

Standard chemical sales shrank, but premium approvals grew.

Neutral

Sales dipped slightly, but one product line carried the weight.

Negative

Custom projects vanished, but factory bills stayed high.

AARTIPHARM Analyst Rating

Hold

Analysts have suggested that investors can Hold this Stock

- By Refinitiv from 1 analysts

Buy

0%

Hold

100%

Sell

0%

Get forecast for Price, ROA & ROE based on analyst ratings.

Get Forecast

AARTIPHARM Latest News

View Allarrow

AARTIPHARM Share Price History

View In-Deptharrow

AARTIPHARM Fundamentals

Company Valuation

Market Cap (₹ Cr.)

7,786

PE Ratio

36.80

PB Ratio

3.70

Dividend Yield

0.40%

ROE

13.69%

ROCE

17.23%

Book Value (₹)

234.30

Face Value (₹)

5.00

Analyse AARTIPHARM with 12+ custom fundamentals and financial ratios.

Analyse Now

Share Holding Pattern

Held ByJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
43.72%42.88%43.10%43.08%42.86%
Domestic Institutional Investors (DII)
7.80%6.96%7.66%7.41%7.22%
Foreign Institutional Investors (FII)
7.35%8.02%7.68%8.39%8.17%
Public Investors
34.43%35.39%34.85%34.29%34.39%
Government
0.01%0.01%0.01%0.01%0.01%

Promoters

Domestic Institutional Investors (DII)

Foreign Institutional Investors (FII)

Public Investors

Government

View In-Deptharrow

Aarti Pharma Labs Return Calculator

You have invested
Investment Period

Current value of ₹1,00,000 invested 4 years ago, as on today

₹ 0

Gain

₹ 1,00,000 (189.66%)

Invest Now

Note: Past profits do not guarantee future returns.

AARTIPHARM Investment Returns

1 Week

1 Month

3 Months

6 Months

9 Months

View In-Deptharrow

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.

Start SIP

AARTIPHARM Technicals

Moving Averages

PeriodSimpleSignal
5-SMA857.33Bullish
10-SMA843.17Bullish
20-SMA841.89Bullish
50-SMA751.91Bullish
100-SMA721.25Bullish
200-SMA719.04Bullish

Technical Indicators

IndicatorValueAction
RSI(14)64.47Neutral
ATR(14)34.85Less Volatile
STOCH(9,6)57.88Neutral
STOCH RSI(14)47.40Neutral
MACD(12,26)-1.60Bearish
ADX(14)33.99Strong Trend

Summary of Technical Indicators for AARTIPHARM

View In-Deptharrow

Margin on AARTIPHARM

Order TypeMargin to PayLeverageQuantityTrade ValueMargin AmountActions

*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).

AARTIPHARM Financials Summary

View By:
Revenue
EBITDA
Net Profit
EPS
Revenue

In Crores

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
388418437596544

AARTIPHARM Financials

View by

Income Statement

In Cr

Quarterly StatementJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
388418437596544
Expenses293344333470400
9574104127144
Operating Profit9474100113136
Operating Profit Margin %24%18%23%19%25%
Other Income205148
Interest711131713
Depreciation2325292830
65396382101
Tax %24%28%24%25%25%
Net Profit5028486176
EPS53578

Balance Sheet

In Cr

Yearly Balance SheetMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
2,0402,2442,5822,9063,482
Fixed Assets7829261,0331,1371,831
Current Assets1,0281,1631,3461,3221,397
Capital Work in Progress187102137374305
Investments328710777640
Other Assets1,0381,1301,3051,3190
2,0402,2442,5822,9063,482
Current Liabilities581601694657938
Non Current Liabilities7385131259420
1,3871,5591,7571,9902,125
Reserve & Surplus1,3411,5131,7121,9452,079
Share Capital045454545
Minority Interest00000

Cash Flow

In Cr

Yearly Cash FlowMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Activities0-44250216332
Investing Activities0-139-158-215-414
Financing Activities0260-1641065
Net Cash Flow078-7112-17
View In-Deptharrow

Corporate Actions

DateCorporate ActionInformation
15th Sept 2026, Tuesday
DIVIDENDDividend
Final Dividend of ₹2/share
7th Aug 2026, Friday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q1 FY 26-27 Results
info
25th May 2026, Monday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q4 FY 26-27 Results
info
16th Feb 2026, Monday
DIVIDENDDividend
Interim Dividend of ₹1.5/share
9th Feb 2026, Monday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q3 FY 25-26 Results
info

The above dates are ex-dates.

View Allarrow

Check AARTIPHARM latest Company Filings, Investor Presentation & Conference Call details.

Read Now

AARTIPHARM Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2024-251,798
18.02% profit
192
28.26% profit
FY 2023-241,786
0.04% profit
257
16.84% profit
FY 2022-231,513
60.31% profit
201
60.9% profit

Top Mutual Funds Invested in AARTIPHARM

AARTIPHARM Popular Brands

AARTIPHARM Similar Stocks

Stock NamePrice
Sun Pharmaceutical

S

Sun Pharmaceutical

1,899.00-0.89%loss
Divis Laboratories

D

Divis Laboratories

9,100.00-1.62%loss
Torrent Pharmaceuticals

T

Torrent Pharmaceuticals

4,857.00-0.99%loss
Zydus Life Science

Z

Zydus Life Science

1,120.00-2.01%loss
Cipla

C

Cipla

1,385.00-0.70%loss
View Allarrow

NSE Indices Today

Index NamePrice
View Allarrow

Top Gainers Today

Stock NamePrice
View Allarrow

Top Losers Today

Stock NamePrice
View Allarrow

Open IPOs

View All IPOsarrow

Calculators

Brokerage Calculator

Brokerage Calculator

Margin Calculator

Margin Calculator

MTF Calculator

MTF Calculator

Stock Return Calculator

Stock Return Calculator

Stock Average Calculator

Stock Average Calculator

View Allarrow

What's New In The Market

View Allarrow

FAQs on AARTIPHARM

Aarti Pharma Labs share price as of today is ₹ 858.80 as on 04 Sep 2026 at 03:50 PM.
The 52W high of Aarti Pharma Labs is ₹ 946.10 and 52W low is ₹ 585.00 as of 04 Sep 2026 at 15:50.
The past returns of Aarti Pharma Labs share are -
  • Past 1 year: -2.32%
  • Past 3 years: 120.77%
  • Past 5 years: 189.66%
The PE and PB ratio of Aarti Pharma Labs stands at 36.80 and 3.70 respectively as on 04 Sep 2026 at 15:50.
The EPS of Aarti Pharma Labs is 8.40 for the quarter ended Jun 2026 and 19.27 for the financial year 2025-26.
The shareholding pattern of Aarti Pharma Labs is as follows:
  • DIIs - 7.22%
  • FII - 8.17%
  • Promoters - 42.86%
  • Public Investors 34.39%
  • Goverenment - 0.01%
Yes, you can buy shares of Aarti Pharma Labs online by opening Demat account with Dhan.
If you are a Dhan user already, you can buy Aarti Pharma Labs stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:
  1. Download the Dhan App to Open a Demat Account
  2. Navigate to the “Money Tab”
  3. Add money to your account
  4. Search for Aarti Pharma Labs share
  5. Tap on “Buy”
With Dhan you can start a daily, weekly or monthly SIP in Aarti Pharma Labs.
You can easily buy the shares of Aarti Pharma Labs even after the markets are closed using the After Market Order feature on Dhan Trading App.


Invest & Trade with a Trading
Platform That's icon

Open your Dhan Account in minutes!


border
logo

Join our Community

community logo

Follow us on

twitter
telegram
Linkedin
youtube
instagram
facebook

built with love
for Indians who love to invest & trade

raise

We are part of Raise Financial Services

raise
raise

Explore  |  Sitemap


*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

We are doing so by giving you access to not just one but 6 products within the Dhan ecosystem:


This means that with Dhan, you'll be able to start:


Lakhs of users already trust Dhan for their online stock trading and investing needs. Dhan is growing rapidly because of the love we receive from SuperTraders and Long-Term Investors who acknowledge that the platform is innovating for them, building super useful features that help them do everything from investing in stock market to trading F&O like a pro on the Tradingview charts and much more.

While we are growing, we will always remember why we started building in the first place - you. Our user-first approach will always be at the heart of our philosophy. Come join us on this incredible journey!

Try it out, you can close your account at anytime using this link.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.

Details of client bank account

For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com store apps sebiscores iOS: https://apps.apple.com app sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution